VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
2.39
+0.15 (+6.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.24
Open2.30
Bid0.00 x 1100
Ask0.00 x 900
Day's Range2.30 - 2.49
52 Week Range1.85 - 4.00
Volume254,843
Avg. Volume141,779
Market Cap71.774M
Beta0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateAug 10, 2018 - Aug 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research3 days ago

    VNRX: Triage Data Expected in Coming Weeks, Frontline By Year-End

    VolitionRx (VNRX) reported Q1 financial results and provided a business update. Initial studies could start in Asia prior to current year-end and if all goes to plan, initial commercial introduction could happen sometime next year.

  • PR Newswire10 days ago

    VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018

    ISNES, Belgium , May 14, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced its participation in the Bank of America Merrill Lynch 2018 Health Care Conference ...

  • Associated Press14 days ago

    VolitionRX: 1Q Earnings Snapshot

    The Singapore-based company said it had a loss of 17 cents per share. In the final minutes of trading on Thursday, the company's shares hit $2.24. A year ago, they were trading at $3.58. _____ This story ...

  • PR Newswire14 days ago

    VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2018. Volition management will host a conference call tomorrow, May 11, at 8:30 a.m. U.S. Eastern Time to discuss these results.

  • PR Newswire15 days ago

    VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

    ISNES, Belgium, May 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a Global Sales and Distribution Agreement with Active Motif for a range of Research Use Only ("RUO") kits, that are based on its proprietary Nucleosomics® technology. Founder and Chairman of Active Motif, Joseph M. Fernandez commented "We are continuously looking for innovative products in the field of epigenetics and believe Nucleosomics® is a breakthrough technology. The RUO kits are based on the same Nu.Q™ immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers.

  • PR Newswire20 days ago

    VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time ISNES, Belgium , May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it ...

  • VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check
    Simply Wall St.2 months ago

    VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check

    VolitionRx Limited (AMEX:VNRX) is a small-cap stock with a market capitalization of US$71.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...

  • ACCESSWIRE2 months ago

    SeeThruEquity Issues Update on VolitionRx (VNRX)

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...

  • ACCESSWIRE2 months ago

    Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests

    Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...

  • PR Newswire2 months ago

    VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

    ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:  VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share for gross proceeds of $8.4 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition.  All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.

  • PR Newswire2 months ago

    VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

    ISNES, Belgium , March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective ...

  • PR Newswire3 months ago

    VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

    Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering.  National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager in connection with the offering. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.

  • PR Newswire3 months ago

    VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

    ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University. Prof. Wei's main area of research is developing statistical methods for the design and analysis of clinical trials. Prof. Wei has developed numerous novel statistical methods used widely and is the author of more than 140 peer-reviewed publications.

  • Zacks Small Cap Research3 months ago

    VNRX: Q4 Results / Operational and Business Update

    By Brian Marckx, CFA NYSE:VNRX VolitionRx (NYSE:VNRX) reported Q4 results and provided a business update.  Relative to the financials, results continue to come in well within our expectations with Q4 operating ...

  • VolitionRx Limited (NYSEMKT:VNRX): Are Analysts Optimistic?
    Simply Wall St.3 months ago

    VolitionRx Limited (NYSEMKT:VNRX): Are Analysts Optimistic?

    VolitionRx Limited’s (AMEX:VNRX): VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The US$84.33M market-cap posted a loss in its most recentRead More...

  • PR Newswire3 months ago

    VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update

    ISNES, Belgium, March 1, 2018 /PRNewswire/ -- VolitionRX Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results for the full fiscal year ended December 31, 2017. Cameron Reynolds, Chief Executive Officer of Volition, upon releasing these results commented, "I could not be more proud of our dedicated team at Volition.  During 2017, we, together with our collaborators, have made strong progress. After seven years of hard work, earlier this week we were excited to announce excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer.

  • PR Newswire3 months ago

    VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update

    Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time ISNES, Belgium , Feb. 28, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference ...

  • PR Newswire3 months ago

    VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

    This ongoing study is being carried out in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program. The interim results demonstrated that a small panel of three ELISA assays, when considered with the subjects' ages and smoking histories, produced an area under the curve (AUC) of 83% and was able to detect 80% of Stage I CRC cases and 66% of High-Risk Adenomas (HRA) at 78% specificity, respectively.

  • PR Newswire4 months ago

    VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

    ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group.  The study was established to answer the very practical, logistical questions of how a triage blood test could fit into the current Danish screening program for colorectal cancer ("CRC"). The study showed that it was indeed possible to collect, process, gather and ship the blood test from all five participating hospitals to a central laboratory within 24 hours. Furthermore, analysis from the central laboratory was shown to provide the needed data in due time (in accordance with current Danish Legislation) to decide whether or not to perform a colonoscopy.

  • PR Newswire5 months ago

    VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

    ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO, Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highlights the fact that the company believes that it is close to achieving a key clinical milestone with the completion of a 680-subject trial for the Nu.QTM Frontline Asymptomatic Colorectal Cancer Screening Test. Volition expects to report the results from this study in early February.

  • PR Newswire6 months ago

    VolitionRx Limited to Attend Conferences in December

    ISNES, Belgium , Dec. 5, 2017 /PRNewswire/ --  VolitionRx Limited  (NYSE American: VNRX) today announced that its Executive Vice President, Scott Powell , is scheduled to attend two conferences in December. ...

  • Zacks Small Cap Research6 months ago

    VNRX: Frontline CRC Studies Read-Out ~1H 2018, Could Be Value-Inflection Event

    By Brian Marckx, CFA NYSE:VNRX Q3 Results / Operational and Business Update:  VolitionRx (NYSE:VNRX) reported Q3 results and provided a business update.  Relative to the financials, results were very much ...

  • PR Newswire6 months ago

    Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

    ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. "The signing of this MOU is a good start for Volition in the Asia Pacific Region" commented Dr. Jasmine Kway, Volition's Vice President of Asia. "We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. The first trial will be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects.

  • ACCESSWIRE6 months ago

    Volitionrx Limited to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Volitionrx Limited (NYSE: VNRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on Friday, November 10, 2017 at 8:30 AM Eastern ...

  • What Investors Should Know About VolitionRx Limited’s (VNRX) Financial Strength
    Simply Wall St.6 months ago

    What Investors Should Know About VolitionRx Limited’s (VNRX) Financial Strength

    Investors are always looking for growth in small-cap stocks like VolitionRx Limited (AMEX:VNRX), with a market cap of USD $78.23M. However, an important fact which most ignore is: how financiallyRead More...